US9873732B2 (ImmuniMed) claims a method for treating CDI by administering an effective amount of egg-derived polyclonal antibody, wherein the CD strain is selected from a group consisting of NAP/B1/027, CCL678, HMC553, Pitt45, CD196, Montreal 5, Montreal 7.1, MH5, Pitt2, CCL14137, UVA17, UVA30/TL42, and Pitt7 [106]. This evidence concerns the gene CCR6 and clostridium difficile infection.